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New Animal Models Minireview
for Parkinson's Disease
areas, and it has not been observed in other neurode-
generative diseases. Other components of the mito-
chondrial respiratory chain are unaffected in PD. Thus,
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in sporadic PD, oxidative stress and mitochondrial dys-Baltimore, Maryland 21287
function appear to play prominent roles in the death of
DA neurons, perhaps through a combination of excito-
toxic, necrotic, and apoptotic mechanisms (see DunnettParkinson's disease (PD) is the second most common
and Bjorklund, 1999 and references therein).progressive neurodegenerative disorder primarily af-
Identification of Familial-Linked PD Genes Yieldfecting individuals between the ages of 50 and 60, al-
New Insight into PD Pathogenesisthough young adults and even children can be affected
The discoveries of genetic linkages for PD provide prom-by this devastating disease (Lang and Lozano, 1998). In
ise for new insights into the pathogenesis of the disease.the last few years, significant progress has been made
Rare missense mutations in a-synuclein (a-syn), A53T,into unraveling the causes of PD. In particular, genes
and A30P cause autosomal dominant PD in a large Ital-linked to familial PD have been identified yielding fresh
ian, American, Greek kindred and a small German pedi-avenues of investigation. In other neurodegenerative
gree, respectively (Polymeropoulos, 1998). a-syn anddisorders animal models of human familial-linked dis-
related family members are abundant neuronal cytosolicease have provided tremendous insight and clues into
proteins enriched at presynaptic terminals and arethe pathogenesis of these disorders. Until recently, there
thought to be involved in synaptic function and plasticityhas not been an animal model of hereditary PD. Two
(Clayton and George, 1998). A truncated fragment of a-synrecent papers by Masliah and colleagues (Masliah et
was also identified as the non-b-amyloid component ofal., 2000) and Feany and Bender (2000) describe such
Alzheimer's disease senile plaques (Ueda et al., 1993).models and provide us with the opportunity to discuss
Following the discovery of the a-syn mutations, a-synrecent advances in our understanding of PD patho-
was quickly discovered to be a major component ofgenesis.
Lewy bodies and neurites, and it is abundant in paleEtiology of Dopamine Neuronal Dysfunction
bodies, which are believed to be the precursor of Lewyand Death
bodies (Trojanowski et al., 1998). Abnormal deposition
PD is due to a relatively selective degeneration of dopa-
of a-syn also occurs in a variety of neurodegenerative
mine (DA) containing neurons in the midbrain. The loss
disorders, many of which have parkinsonian features
of DA neurons is accompanied by the characteristic
(Trojanowski et al., 1998). Wild-type (WT) and mutant
formation of Lewy bodies (cytoplasmic accumulations (A53T and A30P) a-syn self-aggregate and assemble
of aggregated proteins) in cell bodies and neurites. Lewy into fibrils that resemble the ultrastructural elements of
bodies and neurites are mainly found in DA neurons, Lewy bodies (see Conway et al., 2000 and references
but they can be identified in other neuronal systems. therein). The altered conformation of both a-syn mutants
Most Lewy bodies stain abundantly with ubiquitin, a key may somehow contribute to the demise of DA neurons.
player in protein degradation. PD patients experience It is tempting to speculate that the reported decreases
slowness of movement, rigidity, tremor, and difficulty in mitochondrial complex 1 activity and increased oxida-
with balance. Unlike for most other neurodegenerative tive stress in sporadic PD could lead to an oxidative
disorders there is effective temporary symptomatic environment that predisposes WT a-syn to obtain an
treatments for PD involving DA replacement and other altered toxic conformation or promote a-syn fibril forma-
adjunctive medications or surgical approaches (Lang tion (Figure 1). Recent in vitro and in vivo data indicates
and Lozano, 1998). Because the neurodegeneration in that oxidative stress can induce a-syn aggregation (see
PD is progressive and there is no proven preventative, Kowall et al., 2000 and references therein). Whether the
restorative, or regenerative therapy, patients ultimately toxic moiety of a-syn is the altered conformation or
become quite disabled. whether it is the assembly into fibrils that kills DA neu-
The majority of PD is sporadic, although there are rare rons is not known. However, the recent observation that
genetic familial forms of the disease (see below). Insight the A30P a-syn mutant fibrillizes more slowly than WT
into the cause of sporadic PD has come from postmor- or A53T a-syn suggests that fibrils may not be the toxic
tem examination of affected brains. In addition to loss moiety (Conway et al., 2000). On the other hand, both
of DA neurons and the presence of Lewy bodies, there mutants oligomerize more rapidly than WT a-syn poten-
are indications of increased oxidative stress such as tially implicating the process of oligomerization and pro-
glutathione depletion, iron deposition, increased mark- tofibrils in the pathogenesis. It is possible that fibrils
ers of lipid peroxidation, oxidative DNA damage, and and Lewy bodies are an attempt at detoxification of
protein oxidation (Dunnett and Bjorklund, 1999). Another mutant or damaged a-syn (Conway et al., 2000); patho-
logic studies have suggested that Lewy bodies are neu-key postmortem finding is decreased expression and
roprotective (Forno, 1996). In a similar manner, it hasactivity of mitochondrial complex 1 in the midbrain. This
been proposed that nuclear inclusions of polygluta-defect is specific, as it does not occur in other brain
mines in trinucleotide repeat disorders, such as Hunting-
ton's disease and the spinocerebellar ataxias, may serve
a protective role (Orr and Zoghbi, 2000).* E-mail: tdawson@jhmi.edu
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an IBR (in between ring finger) domain. The ring finger
and IBR domains could function as a protein interaction
and/or a transcriptional activator domains. Patients with
mutations in parkin show a severe loss of DA neurons
and the absence of Lewy bodies (Mizuno et al., 1999).
In contrast, Parkin immunoreactivity is present in Lewy
bodies of sporadic PD. The mechanism by which Lewy
body±associated proteins are targeted for degradation
has not been identified. Although speculative in nature,
the absence of Lewy bodies in patients with mutations
in parkin would fit with a hypothesis that Parkin might
be involved in the ubiquitin-mediated degradation of
Lewy body±associated proteins. Consistent with the no-
tion that Parkin might function in the ubiquitin pathway
is the observation that a number of unrelated proteins
with similar ring finger and IBR domains serve as sub-
strates for ubiquitination and may function as ubiquitin-
conjugating enzymes (Lorick et al., 1999). If Parkin is
critical in this process, then in the absence of Parkin,Figure 1. a-Synuclein-Centric Model of DA Cell Death in PD
damaged a-syn would not be ubiquitinated and proteo-a-syn, either through genetic mutation or via oxidative damage
somal degradation would not occur. Lewy bodies wouldthrough decrements in mitochondrial complex 1 and reactive oxy-
gen species (ROS), obtains an altered conformation that promotes not form, damaged a-syn would be free to kill DA neu-
the formation of toxic intermediates and a-syn inclusions. In this rons, and disease would be more severe and occur
model Parkin participates in the detoxification of a-syn by participat- earlier (Figure 1). In this model a-syn could still form
ing in ubiquitin-mediated proteosomal degradation. a-syn could be
inclusions, but they would not be ubiquitinated. It willa target for ubiquitination at the toxic intermediate stage or at insolu-
be of interest to determine whether there are a-syn-ble inclusion stage (not shown). Processes that interfere with the
positive inclusions in patients with mutations of parkin.ubiquitin proteosomal degradation pathway or the formation of
a-syn inclusions could accelerate the death of DA neurons. (See In a similar manner, disruption of ubiquitin-mediated
text for full discussion of model.) degradation of polyglutamine repeat expansions in the
trinucleotide repeat disorders significantly retards the
a-syn also binds to a variety of proteins that could formation of inclusions and accelerates disease (Orr and
ultimately contribute to the toxic properties of a-syn as Zoghbi, 2000).
some of these protein interactions are potentiated by Autosomal dominant familial PD has also been linked
the a-syn mutations. A potentially important interactor is to ubiquitin carboxy-terminal hydrolase L1 on chromo-
synphilin-1. Cotransfection of a truncated form of a-syn, some 4P. Other as yet unidentified genes have been
the nonamyloid component of amyloid plaques (Ueda linked to chromosomes 2P and a different site on 4P
et al., 1993), with synphilin-1 leads to the formation of (see Mizuno et al., 1999 and references therein). Families
cytoplasmic inclusions (Engelender et al., 1999). Fur- with hereditary PD have also been described, but link-
thermore, synphilin-1 is concentrated in Lewy bodies in ages have not yet been associated with any known
PD and diffuse Lewy body disease (Wakabayashi et al., genes or chromosomes. Identification of these genes
will be important in our quest to understand the patho-2000). It is conceivable that mutant or damaged a-syn
interacts with synphilin-1 to create the toxic intermedi- genesis of PD, as understanding the normal physiologi-
cal and pathological actions of these proteins will con-ate. Why would perturbations in a-syn lead to selective
DA neuron death? The propensity of DA cells to degen- tribute insight into the pathogenesis of this disease.
Experimental and Animal Models of PDerate with abnormalities in a-syn may be related to the
unique role of a-syn in DA physiology as mice lacking Insight into the molecular mechanisms of DA cell death
has come from the study of the 6-hydroxydopaminethe gene for a-syn display selective alterations in DA
release, reductions in striatal DA, and attenuation of DA- (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) models of PD (Dunnett and Bjorklund,dependent locomotor response to amphetamine (Abe-
liovich et al., 2000). 1999). Attention has been directed toward the MPTP
model as it more faithfully recapitulates many of theOther genes have been linked to familial PD. Muta-
tions in parkin cause autosomal recessive PD (Mizuno features of sporadic PD. The accidental use of MPTP
by heroin addicts led to the discovery that this toxinet al., 1999). Patients with mutations in parkin develop
many of the features of sporadic PD, but tend to manifest causes PD (see Lang and Lozano, 1998 and references
therein). In humans, nonhuman primates, and rodents,disease at an earlier age including childhood. Most of
the mutations identified are thought to inactivate the MPTP elicits many of the biochemical, neuropathologi-
cal, and clinical features of PD. The active metabolitegene through various homozygous deletions in exons 3
to 7, but recent investigations suggest that missense of MPTP, 1-methyl-4-phenyl pyridium (MPP1), elicits se-
lective DA neuronal degeneration by concentrating inmutations in parkin can also cause PD that appears
indistinguishable from sporadic PD (Abbas et al., 1999). DA neurons via the high-affinity DA transporter. MPP1
is a selective and potent mitochondrial complex 1 inhibi-Parkin is a protein of unknown function, but sequence
homology to ubiquitin in its N terminus suggests that it tor, which led to the discovery of reduced mitochondrial
complex 1 activity in sporadic PD. If it were not for themay function in the ubiquitin protein degradation path-
way. The C terminus contains two ring finger motifs and acute nature of MPTP intoxication, it would be an ideal
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model for sporadic PD. Most of the current theories on and monitor motoric responses of fruit flies to DA
agents. A particularly striking observation in the trans-the mechanisms of cell death in PD stem from studies
of the MPTP model, which has yielded many important genic a-syn fruit flies is the selective loss of DA neurons.
When a-syn is expressed in a panneural distributioninsights (Dunnett and Bjorklund, 1999). MPTP appears
to elicit DA degeneration through inhibition of mitochon- using the elav-GAL4 driver, the flies developed a marked
age-dependent loss of dorsomedial DA neurons. Inter-drial complex 1 and the formation of the superoxide
anion. This coupled with generation of both neuronal- estingly, not all DA neurons degenerate in a-syn trans-
genic flies, as a number of non-dorsomedial TH-positiveand microglial-derived nitric oxide to form peroxynitrite,
which oxidatively injures DA neurons, perhaps through cells remain in aged flies that express a-syn in a
panneural distribution or selectively in DA neurons. ThisDNA damage and activation of poly (ADP-ribose) poly-
merase may be major contributors to DA neuron death is reminiscent of the sparing of subsets of DA neurons
in patients with sporadic PD. The flies develop a-syn-(Grunewald and Beal, 1999). In addition, there is emerg-
ing evidence for neuroinflammation in the pathogenesis positive inclusions and electron microscopy reveals intra-
cytoplasmic inclusions that have a relatively homogenousof MPTP-induced parkinsonism (Liberatore et al., 1999).
The inflammatory component is an attractive target for core and are edged by radiating filaments projecting
into a surrounding halo. The inclusion formation parallelstherapeutic intervention. Interestingly, MPTP adminis-
tration in nonhuman primates induces a-syn aggrega- a-syn toxicity both in its restriction to the nervous sys-
tem and its timing. The overall appearance of the inclu-tion in degenerating DA neurons, thus linking decre-
ments in mitochondrial complex 1, oxidative stress and sions is highly similar to human Lewy bodies. The au-
thors did not show whether these inclusions stain fora-syn aggregation (Kowall et al., 2000) (Figure 1).
The discovery of genes that are linked to familial PD ubiquitin (Lewy bodies are typically enriched in ubiq-
uitin), but the presence of high background ubiquitinprovides us with the opportunity to generate animal
models that may more faithfully recapitulate both the staining in the Drosophila nervous system may prevent
a definitive identification. When a-syn is expressed spe-phenotypic and pathologic features of PD, particularly
with regards to the age-dependent onset and the pro- cifically in the developing and adult eye, retinal degener-
ation occurs in an age-dependent manner and illustratesgressive nature of a degenerative illness. Masliah and
colleagues (Masliah et al., 2000) developed a mouse that degenerative change can occur in nondopaminer-
gic cells similar to neuronal degeneration of non-DAmodel of WT human a-syn overexpression using the
platelet-derived growth factor-b (PDGF-b) promoter. systems in human PD-related syndromes.
How Do These New Models CompareThey characterized five lines of mice that express normal
levels of mouse a-syn plus 10%±80% of a-syn levels to Existing Models?
Although work still needs to be done to fully characterizefound in human brain. All of these transgenic strains
developed neuronal cytoplasmic and nuclear inclusions both models, the major advantage over existing models
is their chronic nature and the presence of a-syn inclu-that stained with antibodies to human a-syn and ubiqui-
tin. Nuclear inclusions are atypical in sporadic PD. The sions. The fact that expression of WT human a-syn elic-
its DA deficits, neuronal inclusions, and motor deficitsinclusions seem to get larger with age, which may be
consistent with a degenerative process. Electron mi- in species as diverse as fruit flies and mice makes it
likely that the alterations induced in these animal modelscroscopy revealed electron-dense inclusions composed
of fine granular material, although no fibrillar aggrega- are also involved in the human disease. The fly model
fulfills most of the criteria for an excellent PD model,tion, which is characteristic of Lewy bodies, was noted.
There was no reported loss of DA neurons, however, including progression, age dependence, selective loss
of DA neurons, and formation of fibrillar a-syn inclusions.in the 12-month-old high-expressing line there was a
significant degeneration of DA nerve terminals. There Although the present mouse model represents a signifi-
cant advance, the fly model is quite compelling andwere also decrements in the levels and catalytic activity
of the rate-limiting enzyme of DA biosynthesis, tyrosine suggests that we should be able to develop a mouse
that recapitulates sporadic PD more faithfully than thehydroxylase (TH), with an accompanying impairment in
rotorod motor performance. It is difficult to say whether present model. Perhaps aging the a-syn transgenic mice
beyond 1 year or increasing the level of neuronal oxida-the motor deficits are due to the small decrements in
TH activity, as symptoms in PD patients and in the MPTP tive stress through pharmacological or genetic means
will produce more significant pathology and DA cell loss.models develop after losing a critical threshold of 60%
to 80% of striatal DA (Dunnett and Bjorklund, 1999). If we extrapolate the findings from Drosophila, we might
need to examine mice that are significantly older thanThis should be readily addressable in future behavioral
studies monitoring the response to DA replacement. one year. Alternatively, expressing higher levels of hu-
man WT a-syn or the mutant a-syn should produceFeany and Bender (2000) have developed a fruit fly
model of PD associated with overexpression of a-syn. transgenic mice with a more severe phenotype.
Do These Transgenic Models Teach Us AnythingWhen normal and mutant forms of a-syn are overex-
pressed in Drosophila, the flies develop an adult-onset New about PD Pathogenesis?
These models are quite persuasive in implicating a-syn(mid-life) progressive loss of DA neurons and filamen-
tous intraneuronal inclusions that contain a-syn. The in the pathogenesis of PD. Due to the timing of a-syn
inclusion formation in the fly, the process and/or forma-transgenic flies also develop progressive age-depen-
dent locomotor dysfunction. It is not yet known, whether tion of a-syn inclusions appear to be the cause of DA
neuron cell death. The mouse model also teaches usthe motor deficits of transgenic flies respond to DA re-
placement, but this should also be easily testable in that a-syn accumulation without the formation of fibrils
leads to DA neuron dysfunction. a-syn inclusions arefuture studies as there are reliable ways to administer
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not restricted to DA neurons and yet none of these other
neuronal subtypes show obvious degeneration. As yet,
neither model yields any specific clues on how a-syn
selectively injures or kills DA neurons. In particular,
questions regarding the role of a-syn fibrils, protofibrils,
oligomers, pale bodies, Lewy bodies, ubiquitination, and
a-syn-interacting proteins in DA neuron cell death re-
main. Furthermore, the relationship and timing of oxida-
tive stress and decrements in mitochondrial complex 1
to a-syn aggregation in sporadic PD remain to be shown.
Whether microglia participate in a-syn-mediated DA
neuron death is not known. However, the fly and mouse
models should prove enormously useful in clarifying
these complex issues. Suppressor and modifier screens
in the fly could also identify important pathways involved
in a-syn toxicity, which could be exploited for novel
therapeutics in the treatment of PD.
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